Aratana Therapeutics Reports Second Quarter 2017 Financial Results


We are pleased with the continued customer adoption of Galliprant and Nocita, stated Steven St. Peter, M.D., President and Chief Executive Officer of Aratana Therapeutics. In addition, we continue to advance our next wave of therapeutic candidates as evidenced by several recent regulatory submissions and a positive pivotal efficacy study in cats. Recent Updates Aratana [ ] The post Aratana Therapeutics Reports Second Quarter 2017 Financial Results appeared first on STL News.
http://bit.ly/2uvAC8L

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s